CD101 Topical: Phase II RADIANT data

Top-line data from 89 patients with moderate to severe acute vulvovaginal candidiasis in the modified intent-to-treat (ITT) population of the open-label, U.S. Phase II RADIANT trial showed that CD101 topical gel and ointment led to clinical cure rates at day 7 of 37.5% and 40%, respectively, vs. 47.4% for fluconazole. Clinical cure was defined as score of 0 points on the VSS, which determines infection severity on a scale of 0 to 3 points for each of 6 signs and symptoms for a maximum score of 18 points. Cidara will discontinue development of the candidate to treat vulvovaginal candidiasis. The company said the discontinuation of CD101 topical will not impact its development of CD101 IV for candidemia and invasive candidiasis...